Oncology and Hematology News and Journal Articles
NLST data clearly demonstrate that lung cancer screening is effective and safe and reduces lung cancer-specific mortality by at least 20%. There is no possible reason for CMS to further delay or restrict lung cancer screening for those at high risk.
If physicians are following the current NCCN and AUA renal cell carcinoma surveillance guidelines, they could be missing as many as one-third of recurrences.
Non-germinal center B-cell-like DLBCL patients derived the most benefit from treatment with the immunochemotherapy regimen R-ACVBP compared with R-CHOP.
Amgen has halted clinical trials of rilotumumab in gastric cancer after a planned safety review showed an increase in the risk of death with the study drug.
Cancer survivors are at an increased risk for developing a second smoking-associated cancer if they smoked cigarettes prior to their first cancer diagnosis.
Researchers are estimating that about 3.6% of new cancer cases in 2012 in adults may be attributed to a high BMI, equating to about 481,000 new cancer cases.
More than 11% of all eligible women had not been screened for cervical cancer in the past 5 years, according to a study by researchers at the CDC.
An oncolytic herpes simplex virus had significant efficacy against ovarian cancer when used alone and in combination with standard chemotherapy treatment.
In this interview we discuss a bovine infectious agent, which may interact with carcinogens that arise during cooking or curing, and play a causative role in certain cancer.
Josh Kremer, MD, vice president of clinical development at Eisai, Inc, discusses results of the phase III SELECT trial, which studied lenvatinib in radioiodine-refractory differentiated thyroid cancer.
In this video, Dr. Sledge discusses what the negative results of the ALTTO trial mean for women with HER2-positive breast cancer.
Dr. Katz describes how he uses social media to learn more about patient perceptions of cancer, how to decide which social media to use, and drawbacks to using social media in a professional capacity.
In this interview we discuss a patient who experienced regression of BRAF-inhibitor-induced eruptive melanocytic nevi following concomitant addition of a MEK inhibitor.
As part of our Society of Neuro-Oncology annual meeting coverage, we discuss quality of life issues and neurologic rehabilitation in patients with neuro-oncologic diseases.
In this interview we discuss the link between soy consumption and breast cancer, and the impact of soy supplements on gene expression in early-stage disease.
In this interview we discuss the use of newly approved agents for chronic lymphocytic leukemia, next-generation therapies in the pipeline, and how the treatment of this type of leukemia has changed.